Scholar Rock Holding Corporation Earnings Recaps
Q2 2026
Aug 8, 2026
Shares rallied 10.5% as Scholar Rock advanced toward the U.S. launch of apitegromab, supported by positive regulatory progress and strong commercial readiness, underpinning confidence in near-term approval and market entry.
Key takeaways
- The U.S. BLA for apitegromab was accepted in April with a PDUFA action date of September 30; FDA review is progressing with two fill/finish facilities providing regulatory flexibility.
- Significant progress at the second fill/finish facility has resulted in more ready vials than the primary Catalent Indiana site, signaling operational strength.
- Commercial preparations for the U.S. launch are well advanced, with the team positioned to launch apitegromab promptly upon approval.
- European regulatory interactions continue, with the EMA awaiting FDA inspection outcomes; planning underway for an initial launch in Germany and expansion into a 50-country footprint.
- The anti-myostatin clinical pipeline shows active development, including Phase II OPAL and FORGE studies and a Phase I trial of a novel antibody, maintaining momentum beyond apitegromab.
Q3 2025
Nov 15, 2025
Scholar Rock faced a setback with its apitegromab application, receiving a complete response letter from the FDA, but remains optimistic about the drug's future approval for spinal muscular atrophy (SMA) thanks to strong clinical data and proactive measures.
Key takeaways
- The FDA's complete response letter cited manufacturing issues, specifically regarding the third-party fill/finish facility, rather than concerns over apitegromab's safety or efficacy.
- Scholar Rock has initiated steps to secure an additional U.S.-based fill/finish facility to enhance production capacity and expedite future submissions.
- The company successfully strengthened its balance sheet in Q3 2025, positioning itself for strategic investments to support long-term growth.
- Regulatory meetings with the FDA were constructive, with plans for resubmission of the BLA anticipated in 2026.
- The Phase II OPAL study for apitegromab in another rare neuromuscular disorder is underway, alongside advancing SRK-439 into clinical trials.